Authors:
EPPENBERGER U
KUENG W
SCHLAEPPI JM
ROESEL JL
BENZ C
MUELLER H
MATTER A
ZUBER M
LUESCHER K
LITSCHGI M
SCHMITT M
FOEKENS JA
EPPENBERGERCASTORI S
Citation: U. Eppenberger et al., MARKERS OF TUMOR ANGIOGENESIS AND PROTEOLYSIS INDEPENDENTLY DEFINE HIGH-RISK AND LOW-RISK SUBSETS OF NODE-NEGATIVE BREAST-CANCER PATIENTS, Journal of clinical oncology, 16(9), 1998, pp. 3129-3136
Authors:
LEROUX JC
COZENS RM
ROESEL JL
GALLI B
DOELKER E
GURNY R
Citation: Jc. Leroux et al., PH-SENSITIVE NANOPARTICLES - AN EFFECTIVE MEANS TO IMPROVE THE ORAL DELIVERY OF HIV-1 PROTEASE INHIBITORS IN DOGS, Pharmaceutical research, 13(3), 1996, pp. 485-487
Authors:
ROGGO BE
PETERSEN F
SILLS M
ROESEL JL
MOERKER T
PETER HH
Citation: Be. Roggo et al., NOVEL SPIRODIHYDROBENZOFURANLACTAMS AS ANTAGONISTS OF ENDOTHELIN AND AS INHIBITORS OF HIV-1 PROTEASE PRODUCED BY STACHYBOTRYS SP .1. FERMENTATION, ISOLATION AND BIOLOGICAL-ACTIVITY, Journal of antibiotics, 49(1), 1996, pp. 13-19
Authors:
LEROUX JC
COZENS R
ROESEL JL
GALLI B
KUBEL F
DOELKER E
GURNY R
Citation: Jc. Leroux et al., PHARMACOKINETICS OF A NOVEL HIV-1 PROTEASE INHIBITOR INCORPORATED INTO BIODEGRADABLE OR ENTERIC NANOPARTICLES FOLLOWING INTRAVENOUS AND ORAL-ADMINISTRATION TO MICE, Journal of pharmaceutical sciences, 84(12), 1995, pp. 1387-1391
Citation: Jl. Roesel et A. Leuthardt, BIOSYNTHESIS, PURIFICATION AND BIOCHEMICAL-CHARACTERIZATION OF A HISTIDINE-LINKED MOMLV PROTEASE, Journal of cellular biochemistry, 1994, pp. 172-172
Authors:
ALTERI E
BOLD G
COZENS R
FAESSLER A
KLIMKAIT T
LANG M
LAZDINS J
PONCIONI B
ROESEL JL
SCHNEIDER P
WALKER M
WOODSCOOK K
Citation: E. Alteri et al., CGP-53437, AN ORALLY BIOAVAILABLE INHIBITOR OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 PROTEASE WITH POTENT ANTIVIRAL ACTIVITY, Antimicrobial agents and chemotherapy, 37(10), 1993, pp. 2087-2092
Citation: A. Leuthardt et Jl. Roesel, CLONING, EXPRESSION AND PURIFICATION OF A RECOMBINANT POLY-HISTIDINE-LINKED HIV-1 PROTEASE, FEBS letters, 326(1-3), 1993, pp. 275-280